Nifelat (Nifedipine)

Nifedipine blocks L‑type calcium channels on arterial smooth‑muscle cells, preventing calcium entry that is necessary for contraction. This causes the arteries to relax and dilate, decreasing systemic vascular resistance and, consequently, lowering arterial blood pressure.

The exact dose of Nifelat is individualized by the prescribing clinician based on the patient’s medical condition, response to therapy, age, renal and hepatic function, and any concomitant medications. No fixed regimen is provided here; the prescriber sets the appropriate strength and frequency.

The safety of nifedipine in pregnancy and lactation has not been definitively established. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified health professional.

To request Nifelat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nifelat (nifedipine) belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes arterial vasodilation. Compared with beta‑blockers or ACE inhibitors, it has a rapid onset of vasodilatory effect and is especially useful when a strong peripheral‑vascular action is desired, but it may be associated with reflex tachycardia.

Nifelat should be stored at ambient temperature, preferably below 25 °C, in its original packaging. The container should be kept tightly closed, protected from moisture and light, and kept out of reach of children.

Nifelat is taken orally, usually with a full glass of water. It may be taken with or without food, but patients should follow the specific instructions given by their prescriber to maintain consistent plasma levels and minimize side‑effects.

The most serious adverse events include severe hypotension, reflex tachycardia, and rare but potentially life‑threatening allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, difficulty breathing, or swelling of the face and throat.

Nifelat is contraindicated in patients with known hypersensitivity to nifedipine or other dihydropyridine calcium‑channel blockers, in those with severe aortic stenosis, and in individuals with cardiogenic shock. Caution is also advised for patients with significant liver impairment or who are taking strong CYP3A4 inhibitors.